文献速递治疗药物监测与药物基因组学

干血斑与血浆采集用于EGFR突变非小细胞肺癌奥希替尼治疗药物监测的初步研究

Therapeutic drug monitoring of osimertinib in EGFR mutant non-small cell lung cancer by dried blood spot and plasma collection: A pilot study.
PubMed 文献 · Br J Clin Pharmacol · 2024-05-05

该前瞻性初步研究纳入21例接受奥希替尼治疗的EGFR突变肺癌患者,用经验证的LC-MS法连续测定药物及主要代谢物浓度,探索剂量与种族间的个体间变异及时间点间的个体内变异。结果显示血浆浓度与干血斑浓度高度相关,不同种族或剂量间浓度无显著差异,支持奥希替尼TDM的可行性及干血斑作为替代定量方法。

要点

  • 奥希替尼血浆与干血斑浓度高度相关,干血斑可作为替代定量方法。
  • 不同种族或剂量间药物浓度无显著差异,时间点间个体内变异无显著差异。
  • 该初步研究支持在更大规模试验中开展奥希替尼及其他靶向治疗的TDM。

核心结论

  • 奥希替尼TDM在临床实践中具有可行性,可支持未来更大规模的试验探索。
  • 干血斑定量可作为传统血浆定量的替代方法,用于奥希替尼及其他靶向治疗的TDM探索。

研究设计与样本

  • 前瞻性初步研究,纳入21例接受奥希替尼治疗的EGFR突变肺癌患者。
  • 采用经验证的液相色谱-质谱联用(LC-MS)法在连续时间点测定奥希替尼及其主要代谢物浓度。
  • 探索按剂量和种族划分的个体间变异以及跨时间点的个体内变异。

主要发现

  • 成功对受试者的奥希替尼及主要代谢物进行了定量。
  • 化合物血浆浓度与干血斑浓度高度相关。
  • 不同种族或剂量间浓度无显著差异,跨时间点个体内变异无显著差异。

关键数值与推荐

  • 奥希替尼及其主要代谢物浓度采用经验证的LC-MS法测定。

临床怎么用

  • 可考虑将干血斑采样作为奥希替尼TDM的血浆替代方法,便于在更大规模试验中推广。

局限性

  • 本研究为纳入21例患者的前瞻性初步研究,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Therapeutic drug monitoring (TDM) has led to significant improvements in individualized medical care, although its implementation in oncology has been limited to date. Tyrosine kinase inhibitors (TKIs) are a group of therapies for which TDM has been suggested. Osimertinib is one such therapy used in the treatment of epidermal growth factor receptor (EGFR) mutation-driven lung cancer. Herein, we describe a prospective pilot study involving 21 patients on osimertinib primarily as a preliminary evaluation of drug levels in a real-world setting. METHODS: Concentrations of the drug and its primary metabolites were measured with a validated liquid chromatography-mass spectrometry (LC-MS) assay across serial timepoints. As part of this study, inter-individual variability by dose and ethnicity as well as intra-individual variability across timepoints are explored. Furthermore, we attempted to validate dried blood spot (DBS)-based quantitation as an accurate alternative to plasma quantitation. RESULTS: Successful quantitation of osimertinib and primary metabolites was achieved for our subjects. Compound plasma levels were highly correlated to DBS levels. There was no significant difference in concentrations with ethnicity or dosing or intra-individual variability across timepoints. CONCLUSIONS: As such, we demonstrate that TDM for osimertinib is practical for future trials. We also validated the use of DBS as an alternative to conventional quantitation for exploration of TDM for osimertinib in larger trials and for other targeted therapies.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Narayanan S, Yuile A, Venkatesh B, et al. Therapeutic drug monitoring of osimertinib in EGFR mutant non-small cell lung cancer by dried blood spot and plasma collection: A pilot study. Br J Clin Pharmacol. 2024. PMID: 38706157. doi:10.1111/bcp.16070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。